← ANALYST RATINGS · TIPRANKS

Carlsmed, Inc. (CARL): analyst forecast and price target

$13.41 −3.87% close 16.10.26 · market cap $381M · General · Medical - Healthcare Information Services IWM 0.01%
Price targets and ratings of

Analyst consensus

Strong Buy

5 Buy0 Hold0 Sell

Ratings of 5 analysts in the last 3 months

12-month forecast

$19.67+46.7% upside

Based on 5 price targets given in the last 3 months, the average target is $19.67, the highest $24.00, the lowest $17.00. The average is +46.7% from the last price of $13.41.

$10.00$15.00$20.00Jan 26AprJulOctJan 27AprJulOctHigh$24.00Average$19.67Low$17.00
Highest target $24.00 Average target $19.67 Lowest target $17.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% BTIG $23.00 → $24.00+4.3% Buy +79.0% Reiterated 12.10.26on TipRanks 08:35 +2.6%next day −2.1%
Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% Truist Financial — Buy — Reiterated 29.09.26on TipRanks 08:11 −0.5%next day +0.1% · 5 days +2.0%
Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% BTIG $23.00 Buy +71.5% Reiterated 28.09.26on TipRanks Sep 29 05:55 −5.3%next day −0.5% · 5 days +6.7%
Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% Bank of America Securities — Buy — Reiterated 13.08.26on TipRanks 11:25 +1.3%next day +2.6% · 5 days +19.9%
Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% Piper Sandler $18.00 Buy +34.2% Reiterated 06.08.26on TipRanks 07:00 +1.2%next day +0.3% · 5 days +0.9%
David Saxon★★★★★★★★★★#6662 · hits 38% · avg +0.8% Needham $17.00 Buy +26.8% Reiterated 06.08.26on TipRanks 06:55 +1.2%next day +0.3% · 5 days +0.9%
David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% Goldman Sachs $17.00 → $16.00−5.9% Buy +19.3% Reiterated 05.05.26on TipRanks May 6 07:30 −2.7%next day +8.9% · 5 days +8.2%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Carlsmed, Inc.

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Ryan Zimmerman★★★★★★★★★★BTIG · #3375
Hits 46%225 of 494 Average return +3.3%
1 year David Roman★★★★★★★★★★Goldman Sachs · #3715
Hits 53%64 of 120 Average return +5.3%
2 years David Roman★★★★★★★★★★Goldman Sachs · #3715
Hits 53%64 of 120 Average return +5.3%

Most profitable

3 months Ryan Zimmerman★★★★★★★★★★BTIG · #3375
Hits 46%225 of 494 Average return +3.3%
1 year David Roman★★★★★★★★★★Goldman Sachs · #3715
Hits 53%64 of 120 Average return +5.3%
2 years David Roman★★★★★★★★★★Goldman Sachs · #3715
Hits 53%64 of 120 Average return +5.3%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.33 at a price of $14.07 (+37.4%); now: $19.67 at $13.41 (+46.7%).

$15.00$20.00Sep 15Oct 1Oct 15Top analysts$23.00Average target$19.67Price$13.41

PriceAverage targetTop analysts’ target

Recommendation trend

051027Oct 2523Nov34Dec56Jan 2645Feb34Mar52Apr8May10Jun61Jul36Aug27Sep36Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy8106323
Buy001676
Hold000000
Sell000000

Earnings and sales forecast

Next report: 05.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.39 (from $-0.42 to $-0.36). Last quarter: $-0.39.

Sales

Next quarter’s sales estimate — $19M (from $18M to $20M). Last quarter: $19M.

Best top-analyst consensus in the sector · General

STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
About Carlsmed, Inc.
  • CEO: Michael Cordonnier
  • Employees: 127
  • 1800 Aston Avenue, Carlsbad, CA, 92008, US
  • www.carlsmed.com

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.

Data from the stock’s TipRanks forecast page, read 85 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗